Sugar Intake Appears to Amplify Antibiotic-Driven Gut Microbiome Injury
Eating more sugar while taking antibiotics may do more than add empty calories. In a study of hospitalized cancer patients, higher sugar intake was tied to deeper disruption of the gut microbiome and a greater rise in potentially harmful bacteria, especially Enterococcus faecium. The pattern matters because antibiotics already strip away part of the microbial ecosystem; sugar appears to give the survivors a better foothold during the recovery period.
Researchers examined 9,419 meals consumed by 173 hospitalized patients with blood cancers and paired those records with daily microbiome sampling. For every additional 100 grams of sugar eaten during the 48 hours before treatment, alpha diversity fell by an additional 21%. Alpha diversity is a measure of how varied the microbial community remains, and lower diversity usually means a gut ecosystem with less resilience and fewer species to block opportunistic organisms from expanding.
The work was published online Sept. 30 in Nature and adds a practical dietary dimension to a problem oncologists and infectious disease clinicians already confront at the bedside. Antibiotics are indispensable, but their collateral effects on the microbiome can be substantial, particularly in hospitalized patients whose diets, immune function, and antimicrobial exposures are all changing at once. In this setting, even short-lived dietary patterns may shape which organisms survive and which ones dominate after the drug pressure begins.
One sentence captures the clinical concern plainly: sugar-rich meals tracked with a less protected gut ecosystem.
Enterococcus Expansion Raises the Stakes in Blood Cancer Care
The signal was not limited to broad diversity loss. Patients who combined sugary diets with antibiotic treatment also showed increases in Enterococcus faecium, a species linked to infections that can be difficult to treat. In blood cancer care, that organism carries particular weight because these patients often undergo chemotherapy, stem cell transplantation, and prolonged hospitalization, leaving them vulnerable to bloodstream and gut-derived infections when the microbiome is weakened.
The investigators focused on this population for a practical reason: food intake could be measured closely, and microbiome samples could be collected every day. That design created unusually dense data for a nutrition-microbiome study, making it possible to connect what patients ate with how their gut microbial communities changed over time. The approach is especially relevant in transplant units, where patients may spend weeks on antibiotics and consume a constrained, highly variable hospital diet.
Marcel van den Brink, MD, PhD, said the microbiome is emerging as an important factor in cancer care and that healthy microbial diversity can influence outcomes, recovery, and side effects during intensive therapy. Jonathan Peled, MD, PhD, added that microbiome injury in blood cancer patients has been associated with worse outcomes, including higher overall mortality and infections. Those clinical consequences are why the study extends beyond nutrition trivia; it touches a pathway that may influence whether a patient stabilizes or spirals during a difficult hospitalization.
The mechanistic logic is straightforward even if the biology remains incompletely mapped. Antibiotics reduce competing bacteria and create empty ecological space. If simple sugars remain abundant in the gut, organisms that can exploit them may grow faster than the rest of the microbial community can recover. In that setting, the problem is not merely loss of microbes; it is selective overgrowth of the wrong ones.
Mouse Data Strengthen the Biological Signal but Not the Clinical Answer
Animal experiments reinforced the human findings. Mice exposed to the antibiotic biapenem while consuming dietary sucrose developed a 16.3-fold increase in the gut Enterococcus population by day 3, and by day 6 the bacterial burden had climbed 33.4-fold. Those are large shifts, and they suggest that sugar is not just riding along as a passive dietary detail. It may be providing a metabolic advantage to organisms already left standing after antibiotic exposure.
William Jogia, a PhD student in Jonas Schluter’s laboratory, described sugar as an amplifier of antibiotic-induced microbiome disruption. He also noted that the exact mechanism remains unresolved. Sugar may directly support Enterococcus, weaken competitor species, or act through some combination of pathways not yet defined in patients. That uncertainty is important, because biological plausibility alone does not prove that changing diet will improve clinical outcomes.
Jonas Schluter, PhD, framed the finding as a potential reason to reduce sweets during and after antibiotic therapy. The language is appropriately cautious. The study points to a modifiable exposure, but it does not establish that cutting sugar prevents infection, accelerates microbiome recovery, or improves survival. Those are the outcomes that matter most for patients, and they still need to be tested in prospective trials.
A second blunt reality follows from the data: the microbiome does not recover in a vacuum.
During intensive cancer treatment, patients are often dealing with chemotherapy-induced mucosal injury, broad-spectrum antibiotics, poor oral intake, and physiologic stress. Sugar intake may seem minor against that backdrop, yet the study suggests it can tilt the microbial balance further toward vulnerability. For clinicians managing transplant candidates and other hospitalized patients with hematologic malignancies, the findings support a simple, low-cost hypothesis worth testing: limiting simple sugars during antibiotic exposure may reduce microbiome injury and blunt the rise of opportunistic organisms.
The next step is a clinical trial designed to answer that question directly. Without that, the field is left with a strong observational and experimental signal, but no proof that dietary sugar reduction changes infections, mortality, or other patient-centered endpoints in the setting of antibiotic exposure.